Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR)

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) are going to reverse split on the morning of Wednesday, October 30th. The 1-10 reverse split was announced on Monday, October 28th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, October 29th.

Kezar Life Sciences Trading Down 1.7 %

NASDAQ:KZR traded down $0.01 on Monday, hitting $0.77. The stock had a trading volume of 1,133,385 shares, compared to its average volume of 738,213. The company has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.69. The stock has a market cap of $56.36 million, a price-to-earnings ratio of -0.57 and a beta of 0.21. Kezar Life Sciences has a 1-year low of $0.52 and a 1-year high of $1.14. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. Equities research analysts expect that Kezar Life Sciences will post -1.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, October 14th.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Fidelis Capital Partners LLC purchased a new stake in Kezar Life Sciences during the 1st quarter worth approximately $25,000. Mackenzie Financial Corp purchased a new stake in Kezar Life Sciences during the 2nd quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Kezar Life Sciences during the 2nd quarter worth approximately $63,000. Marquette Asset Management LLC purchased a new stake in Kezar Life Sciences during the 1st quarter worth approximately $114,000. Finally, BNP Paribas Financial Markets increased its stake in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after buying an additional 71,543 shares during the period. 67.90% of the stock is owned by hedge funds and other institutional investors.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.